πŸ‡ΊπŸ‡Έ FDA
Patent

US 9150514

Dual-acting antihypertensive agents

granted A61KA61K31/415A61K31/4164

Quick answer

US patent 9150514 (Dual-acting antihypertensive agents) held by Theravance Biopharma R&D IP, LLC expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/415, A61K31/4164, A61K31/417, A61K31/4188